BACKGROUND: We aimed to assess the long-term oncologic outcome of hand-assisted laparoscopic radical nephrectomy (HLRN) compared with open radical nephrectomy (ORN) in patients with clinically localized renal cell carcinoma (RCC).
PATIENTS AND METHODS: We retrospectively reviewed the data from 1098 patients who underwent radical nephrectomy at five institutions in Korea between 2000 and 2011 for clinically localized RCC. One hundred ninety-seven patients in the HLRN group were compared with 901 patients in the ORN group. Univariate and multivariate analysis assessed the effects of operative method on oncologic outcomes.
RESULTS: The median duration of follow-up was 69 months for the HLRN group and 63 months for the ORN group. No statistically significant difference was found in the operative time (170.2 minutes versus 168.9 minutes, P=.793) between the HLRN and ORN groups. However, estimated blood loss was significantly lower in the HLRN group than in the ORN group (245.9 mL versus 422.4 mL, P<.001). The pathological T stage was significantly higher in patients in the ORN group: 79.9% of patients in the HLRN group derived from pT1, versus 54.7% of those in the ORN group (P< .001). A statistically significant difference was found in the 5-year disease-free (90.6% versus 79.6%, P< .001), cancer-specific (95.7% versus 91.1%, P=.019), and overall (93.4% versus 85.4%, P< .001) survival between the HLRN and ORN groups. However, multivariate analysis by Cox's proportional hazards model does not retain surgical methods as an independent predictive factor for cancer-related death or recurrence.
CONCLUSIONS: HLRN may be a preferable minimally invasive surgical treatment for clinically localized RCC with comparable long-term oncologic outcomes.
Written by:
Park YH, Lee ES, Kim HH, Kwak C, Ku JH, Lee SE, Byun SS, Hong SK, Kim YJ, Kang SH, Hong SH. Are you the author?
Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
Reference: J Laparoendosc Adv Surg Tech A. 2014 Aug;24(8):556-62.
doi: 10.1089/lap.2014.0035
PubMed Abstract
PMID: 25007232
UroToday.com Renal Cancer Section
